Remus Pharmaceuticals (NSE SME)
May 17, 2023 - May 19, 2023
| Price | ₹1150 - ₹1229 |
| Premium | ₹470 |
|---|---|
| Lot size | 100 |
| Allotment | May 24, 2023 |
| Listing | May 29, 2023 |
| Category | Lot(s) | Qty | Amount | Reserved |
|---|---|---|---|---|
| Retail | 1 | 100 | 122900 | 0 |
| HNI | 2 | 200 | 245800 | 0 |
| Category | Offered | Applied | Times |
|---|---|---|---|
| QIB | 73,700 | 14,92,000 | 20.24 |
| NIB | 55,300 | 95,45,000 | 172.6 |
| RETAIL | 1,29,000 | 48,37,600 | 37.5 |
| Total | 2,58,000 | 1,58,74,600 | 61.53 |
| Retail Apps | 48,376 | © IPO Premium | |
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.
The product offerings of the company can be classified into two major categories:
- APIs: Active Pharmaceutical Ingredient (API) is the biologically active component of a drug product (tablet, capsule, cream, injectable) that produces the intended effects.
- Finished Pharmaceutical Formulations: Finished pharmaceutical formulations are therapeutic drugs available in different dosage forms.
The product portfolio consists of 429 products, as on January 31, 2023. They operate under different brand names across the globe. As on January 31, 2023, the company has 295 products registered in a total of 13 countries. As on January 31, 2023, a total of 134 ;products are under the process of registration in 16 countries.
As on January 31, 2023, Remus Pharmaceuticals had business-to-business supply agreements with 58 domestic distributors and 139 international distributors for distribution and/or contract manufacturing supply.
The company has cultivated strong and dependable customer relationships and its clients are spread in more than 20 countries. These clients range from Generic distributors, regional distributors, and Multinational distributors to Hospitals and Clinics.
Remus Pharmaceuticals IPO Details
| Total Issue Size | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Fresh Issue | 388,000 shares (aggregating up to ₹47.69 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | NSE SME |
Remus Pharmaceuticals IPO Reservation
| QIB Shares Offered | Not more than 50% of the Net Issue |
| NII (HNI) Shares Offered | Not less than 15% of the Net Issue |
| Retail Shares Offered | Not less than 35% of the Net Issue |
| Market Maker portion | 19,500 shares (Sunflower Broking) |
Company Financials
| Period Ended | 31-Mar-20 | 31-Mar-21 | 31-Mar-22 | 31-Dec-22 |
|---|---|---|---|---|
| Total Assets | 530.36 | 1,104.96 | 1,590.93 | 3,352.96 |
| Total Revenue | 1,276.89 | 1,922.45 | 2,543.71 | 3,361.20 |
| Profit After Tax | 81.16 | 102.58 | 338.57 | 643.90 |
| Net Worth | 202.03 | 304.61 | 643.17 | 1,712.07 |
| Reserves and Surplus | 201.03 | 303.61 | 543.17 | 1,603.57 |
| Total Borrowing | 35.93 | 27.89 | 19.17 | 947.45 |
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: remuspharmaceuticals.ipo@linkintime.co.in
Website: https://linkintime.co.in/